Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Rasdegafusp alfa |
| Trade Name | |
| Synonyms | CDX-1401|DEC-205/NY-ESO-1 fusion protein vaccine |
| Drug Descriptions |
Rasdegafusp alfa (CDX-1401) is a DEC-205/NY-ESO-1 fusion protein vaccine that consists of a monoclonal antibody directed against the dendritic cell receptor DEC-205 linked to the tumor-associated antigen DEC-205/NY-ESO-1 fusion protein, which may boost the immune system to attack cancer cells expressing DEC-205/NY-ESO-1 fusion protein (PMID: 24739759). |
| DrugClasses | |
| CAS Registry Number | 1587257-96-2 |
| NCIT ID | C170362 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Guadecitabine + Rasdegafusp alfa | Atezolizumab Guadecitabine Rasdegafusp alfa | 0 | 1 |
| Atezolizumab + Rasdegafusp alfa | Atezolizumab Rasdegafusp alfa | 0 | 1 |
| Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa | Decitabine Nivolumab Poly ICLC Rasdegafusp alfa | 0 | 1 |
| Decitabine + Rasdegafusp alfa | Decitabine Rasdegafusp alfa | 0 | 1 |
| Rasdegafusp alfa | Rasdegafusp alfa | 0 | 4 |